Eli Lilly (LLY)

After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026.

It continues to be pounded by competition and challenges coming from numerous directions.

Market-based odds now show an 87% chance of a rate cut.

Eli Lilly and Co (NYSE: LLY) announced that its diabetes drug, Mounjaro, will be added to China's state-run health insurance scheme from January 1, 2026.

This is no reason to panic.

Eli Lilly offers a stable, growing dividend backed by exceptional profitability and solid financial health, making it a prime pick for long-term dividend growth investors.

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Eli Lilly's stock price and market cap are poised to explode with the GLP-1 market.

The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year.

The report added that at least one of these companies expects to fulfill the multi-billion-dollar investment pledge in full by Jan. 1, 2029.

Despite Agilent Technologies’ underperformance relative to its industry peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

A key catalyst may be right around the corner.

The agency approved the drug for patients who were previously treated with a covalent BTK inhibitor.

There is something for everyone in this excellent list of stocks.

They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.

AI demand is making energy stocks attractive.

As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered army of retail investors. This evolving landscape is characterized by heightened volatility, new thematic rallies, and a significant blurring of

The U.S. stock market is currently navigating a period of cautious optimism, working to regain solid ground after a tumultuous year marked by significant losses in early 2025 and persistent concerns about valuation. While major indices have shown remarkable resilience, underlying economic headwinds and the evolving landscape of artificial

Lee also cited the end of the Federal Reserve’s quantitative tightening program, effective December 1, as a tailwind for U.S. equity markets.

Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect.